Literature DB >> 16319192

Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products.

Vedat Schwenger1, Christian Morath, Alexander Salava, Kerstin Amann, Yuri Seregin, Reinhold Deppisch, Eberhard Ritz, Angelika Bierhaus, Peter P Nawroth, Martin Zeier.   

Abstract

Peritoneal dialysis is limited by morphologic changes of the peritoneal membrane. Use of peritoneal dialysis fluids (PDF) that contain glucose degradation products (GDP) generates advanced glycation end-products (AGE) within the peritoneal cavity. It is unknown whether peritoneal damage is causally related to AGE-receptor for AGE (RAGE) interaction. The effects of PDF were compared with different amounts of GDP on morphologic changes of the peritoneal membrane in 48 wild-type (WT) and 48 RAGE-deficient mice. PDF (1 ml) were instilled twice daily over a period of 12 wk. Groups with eight animals each received no manipulation (sham); sham instillation (sham i.p.); or filter-sterilized, glucose-free, conventional low GDP- or high GDP PDF. In vitro (generation of AGE fluorescence in PDF) and in vivo (immunohistochemistry for carboxymethyllysine), a GDP-dependent increase of AGE formation occurred. Inflammation and neoangiogenesis were augmented in WT mice that were treated with high GDP accompanied by upregulation of CD3+ T cells, increased NF-kappaB binding activity, increased lectin, and vascular endothelial growth factor expression. Furthermore, pronounced submesothelial fibrosis was found with increased expression of TGF-beta1. Exposure to low GDP resulted in only mild inflammation and neoangiogenesis (compared with sham i.p.) and no fibrosis in WT mice. The findings in WT contrasted with those in RAGE-deficient mice, which showed no increased inflammation (CD3+ T cells and NF-kappaB binding activity), neoangiogenesis (by lectin and vascular endothelial growth factor expression), or fibrosis (expression of TGF-beta1) after long-term exposure to GDP-containing PDF. Peritoneal damage by GDP in PDF is dependent at least in part on AGE-RAGE interaction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16319192     DOI: 10.1681/ASN.2005020155

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  33 in total

1.  Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis.

Authors:  Lars P Kihm; Sandra Müller-Krebs; Julia Klein; Gregory Ehrlich; Laura Mertes; Marie-Luise Gross; Antonysunil Adaikalakoteswari; Paul J Thornalley; Hans-Peter Hammes; Peter P Nawroth; Martin Zeier; Vedat Schwenger
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

2.  The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis.

Authors:  Yu-Pei Fan; Ching-Chih Hsia; Kuang-Wen Tseng; Chih-Kai Liao; Tz-Win Fu; Tsui-Ling Ko; Mei-Miao Chiu; Yang-Hsin Shih; Pei-Yu Huang; Yi-Chia Chiang; Chih-Ching Yang; Yu-Show Fu
Journal:  Stem Cells Transl Med       Date:  2015-12-30       Impact factor: 6.940

Review 3.  Encapsulating peritoneal sclerosis in children.

Authors:  Constantinos J Stefanidis; Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2013-11-21       Impact factor: 3.714

4.  Dynamic O-linked N-acetylglucosamine modification of proteins affects stress responses and survival of mesothelial cells exposed to peritoneal dialysis fluids.

Authors:  Rebecca Herzog; Thorsten O Bender; Andreas Vychytil; Katarzyna Bialas; Christoph Aufricht; Klaus Kratochwill
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

Review 5.  Encapsulating peritoneal sclerosis: the state of affairs.

Authors:  Mario R Korte; Denise E Sampimon; Michiel G H Betjes; Raymond T Krediet
Journal:  Nat Rev Nephrol       Date:  2011-08-02       Impact factor: 28.314

Review 6.  Effect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials.

Authors:  Eun-Young Seo; Sook Hee An; Jang-Hee Cho; Hae Sun Suh; Sun-Hee Park; Hyesun Gwak; Yong-Lim Kim; Hunjoo Ha
Journal:  Perit Dial Int       Date:  2014-09-02       Impact factor: 1.756

7.  The C-terminal acidic tail is responsible for the inhibitory effects of HMGB1 on efferocytosis.

Authors:  Sami Banerjee; Arnaud Friggeri; Gang Liu; Edward Abraham
Journal:  J Leukoc Biol       Date:  2010-08-03       Impact factor: 4.962

8.  Neuronal damage and shortening of lifespan in C. elegans by peritoneal dialysis fluid: Protection by glyoxalase-1.

Authors:  Andrea Schlotterer; Friederike Pfisterer; Georgi Kukudov; Britta Heckmann; Daniel Henriquez; Christian Morath; Bernhard K Krämer; Hans-Peter Hammes; Vedat Schwenger; Michael Morcos
Journal:  Biomed Rep       Date:  2018-04-03

9.  Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan.

Authors:  Nobuhiro Ayuzawa; Yoshitaka Ishibashi; Yutaka Takazawa; Haruki Kume; Toshiro Fujita
Journal:  Perit Dial Int       Date:  2011-07-31       Impact factor: 1.756

10.  AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis.

Authors:  Per M Humpert; Ivan K Lukic; Suzanne R Thorpe; Stefan Hofer; Ezzat M Awad; Martin Andrassy; Elizabeth K Deemer; Michael Kasper; Erwin Schleicher; Markus Schwaninger; Markus A Weigand; Peter P Nawroth; Angelika Bierhaus
Journal:  J Leukoc Biol       Date:  2009-04-28       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.